CD8A and neoplasm: NLRP3 activation in dendritic cells by oxaliplatin-treated tumor cells resulted in the release of IL-1β that was critical for priming of anti-tumor CD8+ T cells as depicted in Figure 3B. This knowledge is useful in formulating a therapeutic setting where chemotherapeutic drugs known to activate the NLRP3 inflammasome may be used to improve prognosis.